Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

NCT05287984 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Newly Diagnosed

Interventions

DRUG: Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
DRUG: Zanubrutinib, bendamustine, rituximab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China